Alzheimer’s Disease
Innovative Research and Therapeutic Solutions
Alzheimer’s Disease (AD) is the most common neurodegenerative disorder and the leading cause of dementia worldwide. It gradually impairs memory, thinking, and behavior, eventually interfering with the ability to carry out daily activities and live independently.
Alzheimer’s Disease
Innovative Research and Therapeutic Solutions
Alzheimer’s Disease (AD) is the most common neurodegenerative disorder and the leading cause of dementia worldwide. It gradually impairs memory, thinking, and behavior, eventually interfering with the ability to carry out daily activities and live independently.
Understanding Alzheimer’s and Cognitive Decline
Alzheimer’s Disease (AD) is the most common neurodegenerative disorder and a leading cause of dementia worldwide, affecting an estimated over 55 million people. The risk of developing AD increases sharply with age, with most cases occurring after 65 years old.
Key clinical features include:
Cognitive symptoms:
Memory loss, impaired learning, language difficulties, disorientation
Behavioral and neuropsychiatric symptoms:
Agitation, depression, anxiety, apathy
Functional decline:
Difficulty with daily activities and loss of independence
Neuropathologically, AD is characterized by:
Amyloid-beta plaques deposited outside neurons
Neurofibrillary tangles formed by hyperphosphorylated tau protein inside neurons
Progressive synaptic and neuronal loss, particularly in the hippocampus and cortex, leading to widespread brain dysfunction
Current treatments, including cholinesterase inhibitors, memantine, and recently anti-amyloid antibodies, provide only modest symptomatic benefit or slow disease progression slightly. Importantly, these therapies primarily address cognitive symptoms, while behavioral, psychiatric, and functional impairments remain largely untreated. This underscores a significant unmet medical need for more effective disease-modifying therapies in AD.
Dasher Neuroscience’s Research Strategy for Alzheimer’s
With years of experience in neurodegenerative drug development, we are investigating potential treatments for AD. Our potential candidates have shown encouraging effects on memory and cognition. Through these efforts, we hope to bring new possibilities for patients and families facing this devastating disease.
